Magenta Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Dianthus Therapeutics

12/05/2023 15:50

* Magenta Therapeutics Inc  MGTA.OQ   MGTA.O  is expected
to show
no change in quarterly revenue when it reports  results on May
15 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Magenta
Therapeutics Inc
is for a loss of 41 cents per share. 
    * The one available analyst rating on the shares is
"hold".  
    * The mean earnings estimate of analysts had risen by
about 2.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Magenta
Therapeutics Inc is $1​, above​ its last closing price of $0.68.
​​​

This summary was machine generated May 12 at 14:50 GMT.  All
figures in US dollars  unless otherwise stated